Compositions for treating neurological disorders
The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.
1. A composition comprising a pharmaceutically acceptable carrier or excipient and a synergistic combination of torasemide, or a salt, or sustained release formulation thereof and a compound selected from aminocaproic acid, eplerenone and terbinafine or salt(s), or sustained release formulation(s) thereof, wherein torasemide and the are each provided in a sub-optimal dose.
2. The composition of claim 1 , said composition comprising eplerenone and torasemide.
3. The composition according to claim 1 , wherein said composition contains torasemide and the at least one compound in amounts that are less than one-half (½) the optimal therapeutic dose of each compound.
4. The composition according to claim 1 , wherein said composition contains torasemide and the at least one compound in amounts that are less than one-tenth ( 1/10) the optimal therapeutic dose of each compound.
5. The composition according to claim 1 , wherein said composition contains less than 2.0 mg torasemide.
6. The composition according to claim 5 , wherein said composition contains less than 1 mg torasemide.
7. The composition according to claim 6 , wherein said composition contains less than 0.5 mg torasemide.
8. The composition according to claim 1 , said composition comprising aminocaproic acid and torasemide.
9. The composition according to claim 1 , said composition comprising terbinafine and torasemide.